{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=11", "query": { "condition": "Metastatic Prostate Cancer", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 1273, "total_pages": 128, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T07:59:00.301Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07611110", "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Deutenzalutamide", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 670, "start_date": "2026-05-04", "completion_date": "2030-06-06", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 28, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07611110" }, { "nct_id": "NCT02026960", "title": "RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Renal Cell Carcinoma", "Genitourinary Cancer (Bladder, Prostate or Testicular)" ], "interventions": [ { "name": "RNA extraction and amplification from biopsy specimens", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2014-03", "completion_date": "2017-09-07", "has_results": false, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02026960" }, { "nct_id": "NCT07216248", "title": "Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "relugolix + ARPI.", "type": "DRUG" }, { "name": "Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI", "type": "DRUG" }, { "name": "relugolix or androgen deprivation therapy (ADT) + ARPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 160, "start_date": "2025-10-27", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216248" }, { "nct_id": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer", "Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer", "Head and Neck Cancer", "Differentiated Thyroid Cancer", "Lower Esophageal Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2017-09-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170960" }, { "nct_id": "NCT01353625", "title": "Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Squamous Cell Carcinoma of Head and Neck", "Prostate Cancer", "Ewing's Osteosarcoma", "Chronic Lymphocytic Leukemia", "Neoplasm Metastasis" ], "interventions": [ { "name": "CC-115", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2011-04-25", "completion_date": "2021-03-12", "has_results": false, "last_update_posted_date": "2021-10-05", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01353625" }, { "nct_id": "NCT04383210", "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Pancreatic Cancer", "Lung Cancer", "Head and Neck Cancer", "Breast Cancer", "Kidney Cancer", "Colorectal Cancer", "Bladder Cancer", "Ovarian Cancer", "Sarcoma", "Gallbladder Cancer", "Bile Duct Cancer", "Esophageal Cancer", "Uterine Cancer", "Cholangiocarcinoma", "Prostate Cancer" ], "interventions": [ { "name": "Seribantumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevation Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2020-09-29", "completion_date": "2024-02-28", "has_results": true, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04383210" }, { "nct_id": "NCT06112990", "title": "Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "creatine monohydrate", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Home-based, telehealth", "type": "BEHAVIORAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "BEHAVIORAL" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 200, "start_date": "2023-11-09", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06112990" }, { "nct_id": "NCT06785636", "title": "A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "mCRPC (Metastatic Castration-resistant Prostate Cancer)", "Prostate Cancer" ], "interventions": [ { "name": "Pocenbrodib", "type": "DRUG" }, { "name": "Pocenbrodib and Darolutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pathos AI, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2025-02-07", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 19, "location_summary": "Fountain Valley, California • Los Alamitos, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06785636" }, { "nct_id": "NCT07677267", "title": "A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "115 Years", "sex": "MALE", "summary": "18 Years to 115 Years · Male only" }, "enrollment_count": 1067, "start_date": "2026-06-30", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07677267" }, { "nct_id": "NCT02115828", "title": "A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 9, "start_date": "2014-04", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2018-07-20", "last_synced_at": "2026-10-26T07:59:00.301Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115828" } ] }